Patents by Inventor Robert M. Strieter

Robert M. Strieter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USING SECONDARY LYMPHOID ORGAN CHEMOKINE TO MODULATE PHYSIOLOGICAL PROCESSES IN MAMMALS
    Publication number: 20160058837
    Abstract: The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.
    Type: Application
    Filed: March 31, 2015
    Publication date: March 3, 2016
    Applicants: The Regents of the University of California, The Department of Veterans' Affairs
    Inventors: Steven M. Dubinett, Robert M. Strieter, Sherven Sharma, Raj Batra
  • COMPOSITIONS AND METHODS FOR USING AND IDENTIFYING ANTIMICROBIAL AGENTS
    Publication number: 20120321687
    Abstract: The present invention provides proteins with antimicrobial activity, and methods for treating subjects by administering the proteins. In particular, the invention provides methods for treating and/or preventing microbial diseases and infections. The present invention further provides the target for these antimicrobial agents, as well as assays for identifying regulators of the target.
    Type: Application
    Filed: February 18, 2011
    Publication date: December 20, 2012
    Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Molly A. Hughes, Robert M. Strieter
  • Methods for treating and diagnosing fibrotic and fibroproliferative diseases
    Patent number: 8216796
    Abstract: The present invention provides compositions and methods for diagnosing and treating fibrotic lung disease. In one embodiment the diagnostic method comprises determining the amount of circulating CXCL-12 in a patient relative to a control.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: July 10, 2012
    Assignee: University of Virginia Patent Foundation
    Inventors: Borna Mehrad, Marie D. Burdick, David A. Zisman, Michael P. Keane, John A. Belperio, Robert M. Strieter
  • Methods For Treating And Diagnosing Fibrotic And Fibroproliferative Diseases
    Publication number: 20120094305
    Abstract: The present invention provides compositions and methods for diagnosing and treating fibrotic lung disease. In one embodiment the diagnostic method comprises determining the amount of circulating CXCL-12 in a patient relative to a control.
    Type: Application
    Filed: December 15, 2011
    Publication date: April 19, 2012
    Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Borna Mehrad, Marie D. Burdick, David A. Zisman, Michael P. Keane, John A. Belperio, Robert M. Strieter
  • Methods for treating and diagnosing fibrotic and fibroproliferative diseases
    Patent number: 8114608
    Abstract: The present invention provides compositions and methods for diagnosing and treating fibrotic lung disease.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: February 14, 2012
    Assignee: University of Virginia Patent Foundation
    Inventors: Borna Mehrad, Marie D. Burdick, David A. Zisman, Michael P. Keane, John A. Belperio, Robert M. Strieter
  • Methods for Treating and Diagnosing Fibrotic and Fibroproliferative Diseases
    Publication number: 20100074887
    Abstract: The present invention provides compositions and methods for diagnosing and treating fibrotic lung disease.
    Type: Application
    Filed: November 30, 2007
    Publication date: March 25, 2010
    Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Borna Mehrad, Marie D. Burdick, David A. Zisman, Michael P. Keane, John A. Belperio, Robert M. Strieter
  • Treatment of idiopathic pulmonary fibrosis using IP-10
    Patent number: 7265083
    Abstract: Disclosed are various discoveries concerning the angiogenic and angiostatic properties of the CXC chemokines, including the finding that the ELR motif controls the ability of these molecules to induce angiogenesis. Aspects of the invention include, for example, the identification of IP-10, MIG and certain IL-8 analogues as angiostatic agents, and their use in inhibiting angiogenesis in various systems.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: September 4, 2007
    Assignee: The Regents of The University of Michigan
    Inventors: Robert M. Strieter, Steven L. Kunkel
  • Methods for inhibition of HIV replication using a small molecule inhibitor
    Patent number: 7052676
    Abstract: Methods are provided for inhibiting or suppressing viral replication in an infected host cell. More specifically, methods are provided for inhibiting or suppressing viral replication in an infected host cell by administering compounds that interfere with the binding of C-X-C chemokines to C-X-C chemokine receptors. Such methods are advantageous for treating viral infections such as human immunodefeciency virus infections.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: May 30, 2006
    Assignee: The Regents of the University of Michigan
    Inventors: David M. Markovitz, Brian R. Lane, Peter J. Polverini, Robert M. Strieter
  • Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals
    Publication number: 20040175355
    Abstract: The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.
    Type: Application
    Filed: January 13, 2004
    Publication date: September 9, 2004
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Steven M. Dubinett, Robert M. Strieter, Sherven Sharma, Raj K. Batra
  • Treatment of liver disease and injury with CXC chemokines
    Patent number: 6719969
    Abstract: Disclosed is the surprising discovery that CXC chemokines function to induce rapid hepatocyte proliferation and liver regeneration after injury. The invention thus provides a range of compositions and methods for use in treating liver injury, including those suitable for treating acetaminophen overdose outside the therapeutic window for N-acetyl-cysteine treatment, and those that limit the hepatotoxic side-effects of gene therapy regimens.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: April 13, 2004
    Assignees: The Regents of The University of Michigan, University Court of The University of Edinburgh
    Inventors: Cory M. Hogaboam, Cynthia L. Bone-Larson, Kenneth J. Simpson, Nicholas W. Lukacs, Steven L. Kunkel, Lisa M. Colletti, Robert M. Strieter
  • Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals
    Publication number: 20030175801
    Abstract: The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.
    Type: Application
    Filed: April 18, 2002
    Publication date: September 18, 2003
    Inventors: Steven M. Dubinett, Robert M. Strieter, Sherven Sharma, Raj K. Batra
  • Treatment of idiopathic pulmonary fibrosis using IP-10
    Publication number: 20030031645
    Abstract: Disclosed are various discoveries concerning the angiogenic and angiostatic properties of the CXC chemokines, including the finding that the ELR motif controls the ability of these molecules to induce angiogenesis. Aspects of the invention include, for example, the identification of IP-10, MIG and certain IL-8 analogues as angiostatic agents, and their use in inhibiting angiogenesis in various systems.
    Type: Application
    Filed: March 21, 2002
    Publication date: February 13, 2003
    Applicant: The Regents of The University of Michigan
    Inventors: Robert M. Strieter, Steven L. Kunkel
  • Novel methods for inhibition of HIV replication
    Publication number: 20030026802
    Abstract: Methods are provided for inhibiting or suppressing viral replication in an infected host cell. More specifically, methods are provided for inhibiting or suppressing viral replication in an infected host cell by administering compounds that interfere with the binding of C-X-C chemokines to C-X-C chemokine receptors. Such methods are advantageous for treating viral infections such as human immunodefeciency virus infections.
    Type: Application
    Filed: September 20, 2001
    Publication date: February 6, 2003
    Inventors: David M. Markovitz, Brian R. Lane, Peter J. Polverini, Robert M. Strieter
  • CXC chemokines as regulators of angiogenesis
    Patent number: 6491906
    Abstract: Disclosed are various discoveries concerning the angiogenic and angiostatic properties of the CXC chemokines, including the finding that the ELR motif controls the ability of these molecules to induce angiogenesis. Aspects of the invention include, for example, the identification of IP-10, MIG and certain IL-8 analogues as angiostatic agents, and their use in inhibiting angiogenesis in various systems.
    Type: Grant
    Filed: December 9, 1998
    Date of Patent: December 10, 2002
    Assignee: The Regents of the University of Michigan
    Inventors: Robert M. Strieter, Peter J. Polverini, Steven L. Kunkel
  • Method for treating asthma using SCF antibody
    Patent number: 5911988
    Abstract: This invention provides pharmaceutical compositions comprising anti-SCF antibodies for the reduction of eosinophila in the lungs of mammals. This invention also provides for methods of treating asthma and generating a murine model for asthma.
    Type: Grant
    Filed: August 18, 1997
    Date of Patent: June 15, 1999
    Assignees: Bayer Corporation, Univ. of Michigan
    Inventors: Elise Brownell, Nicholas Lukacs, Steven L. Kunkel, Robert M. Strieter
  • CXC chemokines as regulators of angiogenesis
    Patent number: 5871723
    Abstract: Disclosed are various discoveries concerning the angiogenic and angiostatic properties of the CXC chemokines, including the finding that the ELR motif controls the ability of these molecules to induce angiogenesis. Aspects of the invention include, for example, the identification of IP-10, MIG and certain IL-8 analogues as angiostatic agents, and their use in inhibiting angiogenesis in various systems.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 16, 1999
    Assignee: The Regent of the University of Michigan
    Inventors: Robert M. Strieter, Peter J. Polverini, Steven L. Kunkel
  • Radiolabeled neutrophil activating peptides for imaging
    Patent number: 5605671
    Abstract: A method of imaging a target site in an animal's body in which a labelled chemokine is introduced into the animal's body and allowed to accumulate at a target site which includes corresponding receptor molecules. The accumulated, labelled chemokine material then is detected so as to image the target site of the body.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: February 25, 1997
    Assignees: The Regents of The University of Michigan, Mallinckrodt Medical, Inc.
    Inventors: Leon R. Lyle, Steven L. Kunkel, Robert M. Strieter
  • Therapeutic treatment for inhibiting vascular restenosis
    Patent number: 5571713
    Abstract: A composition suitable for administration to a warm-blooded animal comprising antisense MCP-1 peptide or oligonucleotide or a molecule capable of interacting with MCP-1 peptide or information for its synthesis which may or may not be labeled with a radionuclide by means of a chelate ligand capable of administration to an animal to produce reliable visual imaging of areas of potential restenosis or to produce therapeutic effects on areas of areas of potential restenosis.
    Type: Grant
    Filed: May 27, 1994
    Date of Patent: November 5, 1996
    Assignee: The Regents of the University of Michigan
    Inventors: Leon R. Lyle, Steven L. Kunkel, Robert M. Strieter
  • Labelled monocyte chemoattractant protein material and medical uses thereof
    Patent number: 5413778
    Abstract: A method of imaging a target site in an animal's body in which a labelled CC chemokine or Monocyte Attractant Protein (MCP) material is introduced into the animal's body and allowed to accumulate at a target site which includes MCP receptor molecules. The accumulated, labelled MCP material is then detected so as to image the target site of the body.
    Type: Grant
    Filed: October 5, 1992
    Date of Patent: May 9, 1995
    Assignees: The Regents of the University of Michigan, Mallinckrodt Medical, Inc.
    Inventors: Steven L. Kunkel, Leon R. Lyle, Robert M. Strieter